Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Transcriptional control of viral gene therapy by cisplatin
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):403-410. https://doi.org/10.1172/JCI15548.
View: Text | PDF
Article Genetics

Transcriptional control of viral gene therapy by cisplatin

  • Text
  • PDF
Abstract

Research Article

Authors

James O. Park, Carlos A. Lopez, Vinay K. Gupta, Charles K. Brown, Helena J. Mauceri, Thomas E. Darga, Abdullah Manan, Samuel Hellman, Mitchell C. Posner, Donald W. Kufe, Ralph R. Weichselbaum

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
In vivo regrowth studies. The effect of combined treatment with Ad.Egr.T...
In vivo regrowth studies. The effect of combined treatment with Ad.Egr.TNF.11D and cisplatin was evaluated by measuring the volume of xenografts injected with Ad.Null.3511.11D or Ad.Egr.TNF.11D with or without cisplatin. Day 0 represents the first day of treatment. (a) In Seg-1 xenografts, combined treatment with Ad.Egr.TNF.11D and cisplatin produced significant tumor regression compared with tumors treated with Ad.Null.3511.11D and cisplatin on days 4 (P = 0.045), 6 (P < 0.005), 8 (P < 0.002), 10 (P < 0.001), 12 (P < 0.004), and 14 (P < 0.021). (b) In PROb xenografts, significant tumor regression was observed in the tumors receiving combined treatment with Ad.Egr.TNF.11D and cisplatin compared with tumors treated with Ad.Null.3511.11D and cisplatin on days 4 (P = 0.045), 6 (P < 0.001), 8 (P = 0.048), 10 (P < 0.001), 12 (P < 0.001), and 14 (P = 0.002). Data are reported as mean ± SEM.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts